GSK Adds 325,000 Shares to Treasury in Ongoing Buyback Programme

An announcement from GlaxoSmithKline ( (GB:GSK) ) is now available.

GSK has repurchased 325,000 of its ordinary shares at a volume-weighted average price of 2,179.65 pence, with the stock to be held in treasury as part of its ongoing share buyback programme executed through BNP Paribas. Since the non-discretionary arrangement with the broker began in February, GSK has bought back over 19.1 million shares, lifting treasury holdings to about 6.39% of voting rights and reducing the free float to 4.06 billion shares, a move that can enhance earnings per share and signals continued capital returns to shareholders.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £22.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GSK Stock

According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GSK stock, click here.

More about GlaxoSmithKline

GSK plc is a global biopharmaceutical company focused on developing, manufacturing and marketing prescription medicines, vaccines and consumer healthcare products. The group targets major therapeutic areas including infectious diseases, HIV, oncology and respiratory conditions, and is a large constituent of the U.K. blue-chip equity market.

Average Trading Volume: 9,512,590

Technical Sentiment Signal: Buy

Current Market Cap: £85.13B

Learn more about GSK stock on TipRanks’ Stock Analysis page.